Characterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix Extended-Spectrum β-Lactamase Detection Method

ABSTRACT Production of extended-spectrum β-lactamases (ESBLs) is an important mechanism of β-lactam resistance in Enterobacteriaceae. Identification of ESBLs based on phenotypic tests is the strategy most commonly used in clinical microbiology laboratories. The Phoenix ESBL test (BD Diagnostic Systems, Sparks, Md.) is a recently developed automated system for detection of ESBL-producing gram-negative bacteria. An algorithm based on phenotypic responses to a panel of cephalosporins (ceftazidime plus clavulanic acid, ceftazidime, cefotaxime plus clavulanic acid, cefpodoxime, and ceftriaxone plus clavulanic acid) was used to test 510 clinical isolates of Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Providencia stuartii, Morganella morganii, Enterobacter aerogenes, Enterobacter cloacae, Serratia marcescens, Citrobacter freundii, and Citrobacter koseri. Of these isolates, 319 were identified as ESBL producers, and the remaining 191 were identified as non-ESBL producers based on the results of current phenotypic tests. Combined use of isoelectric focusing, PCR, and/or DNA sequencing demonstrated that 288 isolates possessed blaTEM-1- and/or blaSHV-1-derived genes, and 28 had a blaCTX-M gene. Among the 191 non-ESBL-producing isolates, 77 isolates produced an AmpC-type enzyme, 110 isolates possessed TEM-1, TEM-2, or SHV-1 β-lactamases, and the remaining four isolates (all K. oxytoca strains) hyperproduced K1 chromosomal β-lactamase. The Phoenix ESBL test system gave positive results for all the 319 ESBL-producing isolates and also for two of the four K1-hyperproducing isolates of K. oxytoca. Compared with the phenotypic tests and molecular analyses, the Phoenix system displayed 100% sensitivity and 98.9% specificity. These findings suggest that the Phoenix ESBL test can be a rapid and reliable method for laboratory detection of ESBL resistance in gram-negative bacteria.

[1]  D. Livermore,et al.  Beta-lactamase-mediated resistance and opportunities for its control. , 1998, The Journal of antimicrobial chemotherapy.

[2]  G. Jacoby,et al.  A functional classification scheme for beta-lactamases and its correlation with molecular structure , 1995, Antimicrobial agents and chemotherapy.

[3]  A. Oliver,et al.  Characterization of Clinical Isolates ofKlebsiella pneumoniae from 19 Laboratories Using the National Committee for Clinical Laboratory Standards Extended-Spectrum β-Lactamase Detection Methods , 2001, Journal of Clinical Microbiology.

[4]  P. Hawkey,et al.  Detection of extended-spectrum beta-lactamases in members of the family enterobacteriaceae: comparison of the MAST DD test, the double disc and the Etest ESBL. , 2000, The Journal of antimicrobial chemotherapy.

[5]  V. Jarlier,et al.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. , 1988, Reviews of infectious diseases.

[6]  K. Thomson,et al.  Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests , 1992, Antimicrobial Agents and Chemotherapy.

[7]  A. Oliver,et al.  Nucleotide Sequence and Characterization of a Novel Cefotaxime-Hydrolyzing β-Lactamase (CTX-M-10) Isolated in Spain , 2001, Antimicrobial Agents and Chemotherapy.

[8]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[9]  G. Woods.  Antibacterial susceptibility tests : Dilution and disk diffusion methods. , 1995 .

[10]  Kenneth S. Thomson,et al.  Can Results Obtained with Commercially Available MicroScan Microdilution Panels Serve as an Indicator of β-Lactamase Production among Escherichia coli andKlebsiella Isolates with Hidden Resistance to ExpandedSpectrum Cephalosporins and Aztreonam? , 1998, Journal of Clinical Microbiology.

[11]  Mary Jane Ferraro,et al.  Performance standards for antimicrobial susceptibility testing : twelfth informational supplement , 2002 .

[12]  G. Rossolini,et al.  Molecular Characterization of Extended-Spectrum β-Lactamases Produced by Nosocomial Isolates of Enterobacteriaceae from an Italian Nationwide Survey , 2002, Journal of Clinical Microbiology.

[13]  D. Livermore,et al.  Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. , 1996, The Journal of antimicrobial chemotherapy.

[14]  P. Bradford.  Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat , 2001, Clinical Microbiology Reviews.

[15]  G. Jacoby,et al.  More extended-spectrum beta-lactamases , 1991, Antimicrobial Agents and Chemotherapy.

[16]  K. Thomson,et al.  Detection of Extended-Spectrum β-Lactamases in Members of the Family Enterobacteriaceae: Comparison of the Double-Disk and Three-Dimensional Tests , 1992, Antimicrobial Agents and Chemotherapy.

[17]  A. Agodi,et al.  Repeated epidemics caused by extended-spectrum beta-lactamase-producingSerratia marcescens strains , 1998, European Journal of Clinical Microbiology and Infectious Diseases.

[18]  D. Livermore,et al.  Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. , 2000, The Journal of antimicrobial chemotherapy.

[19]  J. Herrmann,et al.  Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. , 2002, FEMS microbiology letters.

[20]  D. Livermore.  beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.

[21]  A L Barry,et al.  Detection of extended-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test , 1996, Journal of clinical microbiology.

[22]  G. Storch,et al.  CTX-M-5, a Novel Cefotaxime-Hydrolyzing β-Lactamase from an Outbreak of Salmonella typhimuriumin Latvia , 1998, Antimicrobial Agents and Chemotherapy.

[23]  K. Bush,et al.  Ceftazidime-Resistant Klebsiella pneumoniae and Escherichia coli Isolates Producing TEM-10 and TEM-43 β-Lactamases from St. Louis, Missouri , 1998, Antimicrobial Agents and Chemotherapy.

[24]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[25]  G. Jacoby,et al.  Extended-spectrum beta-lactamases , 1989, Antimicrobial Agents and Chemotherapy.

[26]  G. Eliopoulos,et al.  New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  A. Harris,et al.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases. , 1975, Journal of general microbiology.

[28]  D. Livermore,et al.  Bases of variation in resistance to beta-lactams in Klebsiella oxytoca isolates hyperproducing K1 beta-lactamase. , 1997, The Journal of antimicrobial chemotherapy.

[29]  Albert Balows,et al.  Manual of Clinical Microbiology, 7th ed. , 2000 .

[30]  E. S. Moland,et al.  Use of Microdilution Panels with and without β-Lactamase Inhibitors as a Phenotypic Test for β-Lactamase Production among Escherichia coli, Klebsiella spp.,Enterobacter spp., Citrobacter freundii, andSerratia marcescens , 1999, Antimicrobial Agents and Chemotherapy.

[31]  D. Livermore,et al.  Detection of Extended-Spectrum β-Lactamases in Klebsiellae with the Oxoid Combination Disk Method , 2000, Journal of Clinical Microbiology.

[32]  L. Sutton,et al.  Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases , 1994, Journal of clinical microbiology.

[33]  G. Fadda,et al.  Occurrence of Extended-Spectrum β-Lactamases in Members of the Family Enterobacteriaceae in Italy: Implications for Resistance to β-Lactams and Other Antimicrobial Drugs , 2002, Antimicrobial Agents and Chemotherapy.

[34]  G. Griffin.  Cytokines involved in human septic shock--the model of the Jarisch-Herxheimer reaction. , 1998, The Journal of antimicrobial chemotherapy.

[35]  Janice Patterson.  Extended-spectrum -lactamases , 2000 .

[36]  S. Essack,et al.  Laboratory detection of extended-spectrum beta-lactamases (ESBLs)--the need for a reliable, reproducible method. , 2000, Diagnostic microbiology and infectious disease.

[37]  D. Livermore,et al.  Detection of β-lactamase-mediated resistance , 2001 .